From allergic rhinitis to bronchial asthma


DOI: https://dx.doi.org/10.18565/pharmateca.2022.1.85-89

V.A. Revyakina

Research Center for Nutrition and Biotechnology, Moscow, Russia
Allergic rhinitis (AR) is an immune-mediated inflammation of the nasal mucosa caused by contact with an allergen. AR is one of the most common diseases in the world, with prevalence ranging from 10% to 60% depending on the region. In recent years, there has been an increase in cases of comorbid conditions. AR in early childhood is a strong predictor of bronchial asthma (BA) in adolescents and adults. It has been established that AR in preschool children is a high risk factor for the development of atopic BA. Cetirizine (Zodak) maintains a leading role in the treatment of AR. Data from many years of clinical experience confirm that cetirizine has a favorable
safety profile.

About the Autors


Corresponding author: Vera A. Revyakina, Dr. Sci. (Med.), Professor, Head of the Department of Allergology, Federal Research Center for Nutrition and Biotechnology, Moscow, Russia; 5356797@mail.ru; ORCID: https://orcid.org/0000-0002-1149-7927


Similar Articles


Бионика Медиа